DDInter745 DDInter1376
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Fludarabine {u} (Compound) resembles {v} (Compound) Adenosine triphosphate
Fludarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Fludarabine {u} (Compound) binds {v} (Gene) POLA1
Fludarabine {u} (Compound) causes {v} (Side Effect) Discomfort
Fludarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Fludarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ofloxacin
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Fludarabine {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Fludarabine {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Fludarabine (Compound) resembles Adenosine triphosphate (Compound)
Fludarabine (Compound) treats hematologic cancer (Disease)
Fludarabine (Compound) binds POLA1 (Gene)
Fludarabine (Compound) causes Discomfort (Side Effect)
Fludarabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Fludarabine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Fludarabine may lead to a major life threatening interaction when taken with Natalizumab
Fludarabine may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen